• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

多发性硬化症中的分子生物标志物与认知障碍:该领域现状、局限性及未来方向——一项系统综述与荟萃分析

Molecular biomarkers and cognitive impairment in multiple sclerosis: State of the field, limitations, and future direction - A systematic review and meta-analysis.

作者信息

Rademacher Tom-D, Meuth Sven G, Wiendl Heinz, Johnen Andreas, Landmeyer Nils C

机构信息

Department of Neurology, University Hospital Münster, Germany.

Department of Neurology, University Hospital Düsseldorf, Germany.

出版信息

Neurosci Biobehav Rev. 2023 Mar;146:105035. doi: 10.1016/j.neubiorev.2023.105035. Epub 2023 Jan 3.

DOI:10.1016/j.neubiorev.2023.105035
PMID:36608917
Abstract

OBJECTIVE

Multiple sclerosis (MS) is associated with cognitive impairment (CI) such as slowed information processing speed (IPS). Currently, no immunocellular or molecular markers have been established in cerebrospinal fluid and serum analysis as surrogate biomarkers with diagnostic or predictive value for the development of CI. This systematic review and meta-analysis aims to sum up the evidence regarding currently discussed markers for CI in MS.

METHODS

A literature search was conducted on molecular biomarkers of CI in MS, such as neurofilament light chain, chitinases, and vitamin D.

RESULTS

5543 publications were screened, of which 77 entered the systematic review. 13 studies were included in the meta-analysis. Neurofilament light chain (CSF: r = -0.294, p = 0.003; serum: r = -0.137, p = 0.001) and serum levels of vitamin D (r = 0.190, p = 0.014) were associated with IPS outcomes.

CONCLUSIONS

Neurofilament light chain and vitamin D are promising biomarkers to track impairments in IPS in MS. Further longitudinal research is needed to establish the use of molecular biomarkers to monitor cognitive decline.

摘要

目的

多发性硬化症(MS)与认知障碍(CI)相关,如信息处理速度(IPS)减慢。目前,在脑脊液和血清分析中尚未确立免疫细胞或分子标志物作为CI发生的具有诊断或预测价值的替代生物标志物。本系统评价和荟萃分析旨在总结关于MS中目前讨论的CI标志物的证据。

方法

对MS中CI的分子生物标志物进行文献检索,如神经丝轻链、几丁质酶和维生素D。

结果

筛选了5543篇出版物,其中77篇进入系统评价。13项研究纳入荟萃分析。神经丝轻链(脑脊液:r = -0.294,p = 0.003;血清:r = -0.137,p = 0.001)和血清维生素D水平(r = 0.190,p = 0.014)与IPS结果相关。

结论

神经丝轻链和维生素D是追踪MS中IPS损伤的有前景的生物标志物。需要进一步的纵向研究来确立分子生物标志物在监测认知衰退中的应用。

相似文献

1
Molecular biomarkers and cognitive impairment in multiple sclerosis: State of the field, limitations, and future direction - A systematic review and meta-analysis.多发性硬化症中的分子生物标志物与认知障碍:该领域现状、局限性及未来方向——一项系统综述与荟萃分析
Neurosci Biobehav Rev. 2023 Mar;146:105035. doi: 10.1016/j.neubiorev.2023.105035. Epub 2023 Jan 3.
2
The association of apolipoprotein E (ApoE) genotype and cognitive outcomes in multiple sclerosis; a systematic review and meta-analysis.载脂蛋白 E (ApoE) 基因型与多发性硬化认知结局的相关性:系统评价和荟萃分析。
Mult Scler Relat Disord. 2022 Sep;65:104011. doi: 10.1016/j.msard.2022.104011. Epub 2022 Jul 3.
3
CSF tau and the CSF tau/ABeta ratio for the diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI).脑脊液tau蛋白及脑脊液tau蛋白与β淀粉样蛋白比值在轻度认知障碍(MCI)患者中用于诊断阿尔茨海默病性痴呆及其他痴呆。
Cochrane Database Syst Rev. 2017 Mar 22;3(3):CD010803. doi: 10.1002/14651858.CD010803.pub2.
4
What is the value of routinely testing full blood count, electrolytes and urea, and pulmonary function tests before elective surgery in patients with no apparent clinical indication and in subgroups of patients with common comorbidities: a systematic review of the clinical and cost-effective literature.在没有明显临床指征的患者和常见合并症患者亚组中,在择期手术前常规检测全血细胞计数、电解质和尿素以及肺功能测试的价值:对临床和成本效益文献的系统评价。
Health Technol Assess. 2012 Dec;16(50):i-xvi, 1-159. doi: 10.3310/hta16500.
5
Vitamin D for the management of multiple sclerosis.维生素D用于多发性硬化症的管理。
Cochrane Database Syst Rev. 2018 Sep 24;9(9):CD008422. doi: 10.1002/14651858.CD008422.pub3.
6
Folic acid with or without vitamin B12 for cognition and dementia.叶酸联合或不联合维生素B12对认知及痴呆的影响
Cochrane Database Syst Rev. 2003(4):CD004514. doi: 10.1002/14651858.CD004514.
7
Memory rehabilitation for people with multiple sclerosis.针对多发性硬化症患者的记忆康复治疗。
Cochrane Database Syst Rev. 2016 Mar 23;3:CD008754. doi: 10.1002/14651858.CD008754.pub3.
8
Nutritional interventions for survivors of childhood cancer.儿童癌症幸存者的营养干预措施。
Cochrane Database Syst Rev. 2016 Aug 22;2016(8):CD009678. doi: 10.1002/14651858.CD009678.pub2.
9
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.系统性药理学治疗慢性斑块状银屑病:网络荟萃分析。
Cochrane Database Syst Rev. 2021 Apr 19;4(4):CD011535. doi: 10.1002/14651858.CD011535.pub4.
10
Signs and symptoms to determine if a patient presenting in primary care or hospital outpatient settings has COVID-19.在基层医疗机构或医院门诊环境中,如果患者出现以下症状和体征,可判断其是否患有 COVID-19。
Cochrane Database Syst Rev. 2022 May 20;5(5):CD013665. doi: 10.1002/14651858.CD013665.pub3.

引用本文的文献

1
Neurofilament Light Chain and Disability Measures as Predictors of Cognitive Decline in Early Multiple Sclerosis.神经丝轻链和残疾指标作为早期多发性硬化症认知衰退的预测因素
Med Sci Monit. 2025 Jul 25;31:e948757. doi: 10.12659/MSM.948757.
2
Cognitive Impairment in Newly Diagnosed Patients with Multiple Sclerosis: A Systematic Review of Related Molecular Biomarkers and a Meta-Analysis of Associated Demographic and Disease-Related Characteristics.新诊断多发性硬化症患者的认知障碍:相关分子生物标志物的系统评价及相关人口统计学和疾病相关特征的荟萃分析
J Clin Med. 2025 Apr 11;14(8):2630. doi: 10.3390/jcm14082630.
3
Attitudes of Neurologists Toward Serum Neurofilament Light-Chain Testing in the Management of Relapsing-Remitting Multiple Sclerosis with Cognitive Impairment.
神经科医生对血清神经丝轻链检测在伴认知障碍的复发缓解型多发性硬化管理中的态度
J Pers Med. 2025 Feb 14;15(2):69. doi: 10.3390/jpm15020069.
4
Biomarkers of Intrathecal Synthesis May Be Associated with Cognitive Impairment at MS Diagnosis.鞘内合成生物标志物可能与多发性硬化症诊断时的认知障碍有关。
Int J Mol Sci. 2025 Jan 19;26(2):826. doi: 10.3390/ijms26020826.
5
Functional and Cognitive Impairment in Patients with Relapsing-Remitting Multiple Sclerosis: Cognitive Tests and Plasma Neurofilament Light Chain Levels.复发缓解型多发性硬化症患者的功能和认知障碍:认知测试与血浆神经丝轻链水平
Medicina (Kaunas). 2025 Jan 3;61(1):70. doi: 10.3390/medicina61010070.
6
The contribution of paramagnetic rim and cortical lesions to physical and cognitive disability at multiple sclerosis clinical onset: evaluating the power of MRI and OCT biomarkers.在多发性硬化症的临床发病中,顺磁边缘和皮质病变对身体和认知残疾的贡献:评估 MRI 和 OCT 生物标志物的效力。
J Neurol. 2024 Oct;271(10):6702-6714. doi: 10.1007/s00415-024-12622-8. Epub 2024 Aug 19.
7
Cognitive impairment in multiple sclerosis: from phenomenology to neurobiological mechanisms.多发性硬化症的认知障碍:从现象学到神经生物学机制。
J Neural Transm (Vienna). 2024 Aug;131(8):871-899. doi: 10.1007/s00702-024-02786-y. Epub 2024 May 18.
8
The Blood Concentration of Metallic Nanoparticles Is Related to Cognitive Performance in People with Multiple Sclerosis: An Exploratory Analysis.金属纳米颗粒的血药浓度与多发性硬化症患者的认知表现相关:一项探索性分析。
Biomedicines. 2023 Jun 25;11(7):1819. doi: 10.3390/biomedicines11071819.
9
Chitinase-3-like 1-protein in CSF: a novel biomarker for progression in patients with multiple sclerosis.脑脊液中的几丁质酶-3 样蛋白 1:多发性硬化症患者进展的新型生物标志物。
Neurol Sci. 2023 Sep;44(9):3243-3252. doi: 10.1007/s10072-023-06764-2. Epub 2023 Mar 29.